Merck & Co anticipates lower sales by 2026 due to patent expirations on key medications, including the diabetes drug Januvia.
Merck & Co forecasts lower 2026 sales and profits due to post-patent challenges for key drugs like Januvia, despite strong performance from Keytruda. The company's proactive measures include ...
(The Center Square) – Negotiated lower Medicare costs for 10 popular prescription drugs went into effect Thursday. How much those savings will be passed on to Medicare Part D and applicable Advantage ...
The Manila Times on MSN
Merck forecasts 2026 sales below estimates on patent losses
MERCK & Co. on Tuesday forecast 2026 sales and profits below Wall Street estimates, as the loss of patent exclusivity on diabetes drug Januvia and other medicines will hit harder than analysts are ...
Januvia (sitagliptin) is a medication for type 2 diabetes. Along with diet and exercise, it can help lower blood sugar levels. Medicare Part D will generally cover prescription drugs, like Januvia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results